Invention Grant
- Patent Title: Compounds for immunoproteasome inhibition
- Patent Title (中): 化合物免疫蛋白酶体抑制
-
Application No.: US13580112Application Date: 2011-03-01
-
Publication No.: US09359398B2Publication Date: 2016-06-07
- Inventor: Kevin D. Shenk , Francesco Parlati , Mark K. Bennett
- Applicant: Kevin D. Shenk , Francesco Parlati , Mark K. Bennett
- Applicant Address: US CA South San Francisco
- Assignee: Onyx Therapeutics, Inc.
- Current Assignee: Onyx Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Marshall, Gerstein & Borun LLP
- International Application: PCT/US2011/026629 WO 20110301
- International Announcement: WO2011/109355 WO 20110909
- Main IPC: A01N37/18
- IPC: A01N37/18 ; A61K38/00 ; A61P31/00 ; A61P29/00 ; A61P3/04 ; A61P25/00 ; A61P35/00 ; A61K38/06 ; A61K38/07 ; C07K5/00 ; C07K7/00 ; C07K16/00 ; C07K17/00 ; C07K5/08 ; C07D209/20 ; C07D241/24 ; C07D295/104 ; C07D303/36 ; C07D405/12
Abstract:
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
Public/Granted literature
- US20130072422A1 COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION Public/Granted day:2013-03-21
Information query
IPC分类:
